Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Assets (2018 - 2025)

Dna X filings provide 8 years of Assets readings, the most recent being $43.9 million for Q4 2025.

  • On a quarterly basis, Assets rose 10.47% to $43.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $43.9 million, a 10.47% increase, with the full-year FY2025 number at $43.9 million, up 10.47% from a year prior.
  • Assets hit $43.9 million in Q4 2025 for Dna X, up from $40.2 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $58.6 million in Q3 2023 to a low of $36.0 million in Q1 2025.
  • Median Assets over the past 5 years was $41.7 million (2021), compared with a mean of $44.5 million.
  • Biggest five-year swings in Assets: plummeted 42.8% in 2021 and later skyrocketed 44.11% in 2023.
  • Dna X's Assets stood at $41.1 million in 2021, then soared by 30.65% to $53.7 million in 2022, then increased by 4.39% to $56.0 million in 2023, then decreased by 29.09% to $39.7 million in 2024, then increased by 10.47% to $43.9 million in 2025.
  • The last three reported values for Assets were $43.9 million (Q4 2025), $40.2 million (Q3 2025), and $36.1 million (Q2 2025) per Business Quant data.